true 0001389545

 0001389545

 2023-01-01
 2023-12-31

 0001389545

 2023-06-30

 0001389545

 2024-03-21

 UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 FORM 10-K/A

 Amendment No. 1

 (Mark One)

 ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the fiscal year ended December 31, 2023

 --12-31FY2023

 OR

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 For the transition period from to

 Commission file number 001-33678

 NOVABAY PHARMACEUTICALS, INC.

 (Exact name of registrant as specified in its charter)

 Delaware

 68-0454536

 (State or other jurisdiction of incorporation or

 organization)

 (I.R.S. Employer Identification No.)

 2000 Powell Street, Suite 1150, Emeryville, California 94608

 (Address of principal executive offices) (Zip Code)

 Registrant's Telephone Number, Including Area Code: ( 510) 899-8800

 Securities Registered Pursuant to Section 12(b) of the Act:

 Title of Each Class

 Trading Symbol(s)

 Name of Each Exchange On Which Registered

 Common Stock, par value $0.01 per share

 NBY

 NYSE American

 Securities Registered Pursuant to Section 12(g) of the Act: None.

 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

 Yes No

 Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

 Yes No

 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

 Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):

 Large accelerated filer

 Accelerated filer

 Emerging growth company

 Non-accelerated filer

 Smaller reporting company

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act by the registered public accounting firm that prepared or issued its audit report.

 If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

 Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b).

 Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

 As of June 30, 2023, the aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the last sale price of such stock as of such date on the NYSE American, was approximately $ 3,050,485. This figure excludes an aggregate of 159,265 shares of common stock held by affiliates, including officers and directors, as of June 30, 2023. Exclusion of shares held by any of these persons should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant.

 As of March 21, 2024, there were 30,098,150 shares of the registrant's common stock outstanding.

 Auditor firm ID

 Auditor Name

 Auditor Location

 PCAOB ID No. 100

 WithumSmith+Brown, PC

 San Francisco, California

 DOCUMENTS INCORPORATED BY REFERENCE

 None.

 EXPLANATORY NOTE

 This Amendment No. 1 on Form 10-K/A (this "Amendment") amends the Annual Report on Form 10-K of NovaBay Pharmaceuticals, Inc. for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission on March 26, 2024 (the "Original Filing"). Exhibit 4.1 (Description of Securities) (the "Description of Securities") was inadvertently omitted in the Original Filing.

 This Amendment is being filed solely to file the Description of Securities. No other changes were made to the Original Filing. Further, no attempt has been made in this Amendment to modify or update the other disclosures presented in the Original Filing. This Amendment does not reflect events occurring after the filing of the Form 10-K (i.e., occurring after March 26, 2024) or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment should be read in conjunction with the Original Filing and the registrant's other filings with the Securities and Exchange Commission.

 In accordance with Rule 12b-15 of the Securities Exchange Act of 1934, as amended, this Amendment includes new certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002, as amended, dated as of the filing date of this Amendment.

 ITEM 15.

 EXHIBITS, FINANCIAL STATEMENT SCHEDULES

 (a) Documents filed as part of this report:

 (1) Financial Statements. f inancial s tatements are not included in this Amendment. See the consolidated financial statements of NovaBay Pharmaceuticals, Inc. included in Part II, Item 8 of the Original Filing.

 (2) Financial Statement Schedules. All schedules have been omitted because they are not required or the required information is included in our consolidated financial statements and notes thereto.

 (3) Exhibits. The following exhibits are filed as part of this Report:

 Incorporation by Reference

 Filed

 Herewith

 Exhibit

 Number

 Exhibit Description

 Form

 File

 Number

 Exhibit/

 Form 8-K

 Item

 Reference

 Filing

 Date

 2.1

 Membership Unit Purchase Agreement dated September 27, 2021, by and among the Company, DERMAdoctor, the Founders and the Sellers (as defined therein)

 001-3678

 2.1

 9/28/2021

 2.2

 Membership Unit Purchase Agreement dated March 12, 2024, but and among the Company, DERMAdoctor, and New Age Investments

 001-3678

 2.1

 03/14/2024

 3.1

 Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc.

 3.1

 3/21/2018

 3.2

 Amendment to the Amended and Restated Certificate of Incorporation, dated June 4, 2018

 3.1

 6/04/2018

 3.3

 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 27, 2020

 3.1

 5/28/2020

 3.4

 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021

 3.1

 5/24/2021

 3.5

 Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated January 31, 2022

 3.1

 2/1/2022

 3.6

 Amendment to Amended and Restated Certificate of Incorporation, as amended, dated November 14, 2022

 3.1

 11/18/2022

 3.7

 Certificate of Designation for the Series B Preferred Stock

 3.1

 11/1/2021

 3.8

 Certificate of Designation for the Series C Preferred Stock

 3.2

 11/18/2022

 3.9

 Bylaws, as amended and restated effective June 13, 2023

 3.7

 6/14/2023

 4.1

 Description of Securities

 4.1

 3/31/2023

 4.2

 Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020

 4.1

 5/18/2020

 4.3

 Form of July 2020 Warrant

 4.1

 7/21/2020

 4.4

 Form of Amended July 2020 Warrant

 4.1

 4.5

 Form of Amended November 2021 Warrant

 4.2

 4.6

 Form of September 2022 Warrant (2020 participants)

 4.3

 4.7

 Form of September 2022 Warrant (2021 participants)

 4.4

 4.8

 Form of Series A-1 Long-Term Warrant

 4.5

 4.9

 Form of Series A-2 Short-Term Warrant

 4.6

 4.10

 Form of Original Issue Discount Secured Senior Convertible Debentures

 4.1

 4.11

 Form of Series B-1 Long-Term Warrant

 4.2

 4.12

 Form of Series B-2 Short-Term Warrant

 4.3

 4.13

 Form of Warrant Amendment Agreement

 4.4

 4.14

 Form of Series C Common Stock Warrant

 4.1

 12/21/2023

 4.15

 Form of Series D Common Stock Warrant

 4.2

 3/25/2024

 4.16

 Form of Unsecured Convertible Notes

 4.3

 3/25/2024

 10.1

 Director and Officer Indemnity Agreement

 10.1

 3/29/2022

 10.2+

 NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan (as amended and restated)

 S-8

 333-215680

 99.1

 1/24/2017

 10.3+

 NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan

 S-8

 333-218469

 99.1

 6/02/2017

 10.4+

 NovaBay Pharmaceuticals, Inc. 2017 Omnibus Incentive Plan (Form Agreements to the 2017 Omnibus Incentive Plan)

 S-8

 333-218469

 99.2

 6/02/2017

 10.5+

 Executive Employment Agreement (Employment Agreement of Justin M. Hall)

 10.1

 2/6/2020

 10.6+

 First Amendment to the Executive Employment Agreement with Justin M. Hall, dated January 26, 2022

 10.6

 1/28/2022

 10.7+

 Second Amendment to Executive Employment Agreement with Justin M. Hall, effective December 31, 2023

 10.3

 12/11/2023

 10.8+

 2024 Non-Employee Director Compensation Plan

 10.8

 3/26/2024

 10.9

 Office Lease (between the Company and KBSIII Towers at Emeryville, LLC)

 10.1

 8/26/2016

 10.10

 First Amendment to Office Lease by and between the Company and KBSIII Towers at Emeryville, LLC, dated January 24, 2022

 10.2

 1/28/2022

 10.11

 International Distribution Agreement (by and between the Company and Pioneer Pharma Co. Ltd.)

 10.18

 3/27/2012

 10.12

 At the Market Offering Agreement between the Company and Ladenburg Thalmann & Co. Inc., dated May 14, 2021

 1.1

 5/14/2021

 10.13

 Form of Exercise Agreement with Holders of 2019 Domestic Warrants

 10.1

 7/21/2020

 10.14

 Form of Exercise Agreement with Holders of 2019 Foreign Warrants

 10.2

 7/21/2020

 10.15

 Form of Reprice Agreement with Ladenburg

 10.3

 7/21/2020

 10.16

 Form of Securities Purchase Agreement, dated October 29, 2021

 1.1

 11/01/2021

 10.17

 Form of Registration Rights Agreement, dated October 29, 2021

 10.1

 11/01/2021

 10.18

 Form of 2020 Warrant Reprice Letter Agreement, dated September 9, 2022

 10.1

 10.19

 Form of 2021 Warrant Reprice Letter Agreement, dated September 9, 2022

 10.2

 10.20

 Form of Securities Purchase Agreement, dated September 9, 2022

 10.3

 10.21

 Form of Registration Rights Agreement

 10.4

 10.22+

 Consulting Agreement between the Company and Andrew Jones, dated February 15, 2023

 10.8

 3/31/2023

 10.23

 Form of Letter Agreement

 10.1

 12/21/2023

 10.24*

 License and Distribution Agreement by and between NovaBay and Sonoma, dated, January 5, 2024

 10.1

 1/05/2024

 10.25

 Form of Securities Purchase Agreement

 10.1

 10.26*

 Form of Security Agreement

 10.2

 10.27*

 Form of First Amendment to the Security Agreement, dated March 24, 2024

 10.3

 3/25/2024

 10.28

 Form of Subsidiary Guarantee

 10.3

 10.29*

 Form of Consent and Release, dated March 24, 2024

 10.4

 3/25/2024

 10.30

 Form of Voting Commitment

 10.4

 10.31

 Form of Registration Rights Agreement

 10.5

 Subsidiaries of the Company

 3/26/2024

 23.1

 Consent of WithumSmith+Brown PC

 23.1

 3/26/2024

 31.1

 Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)

 X

 31.2

 Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a)

 X

 32.1

 Certification by the Chief Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)

 X

 32.2

 Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350)

 X

 NovaBay Pharmaceuticals, Inc. Policy for Recoupment of Incentive Compensation

 3/26/2024

 101.INS

 X

 101.SCH

 X

 101.CAL

 X

 101.DEF

 X

 101.LAB

 X

 101.PRE

 X

 X

 +

 Indicates a management contract or compensatory plan or arrangement

 NovaBay Pharmaceuticals, Inc. has been granted confidential treatment with respect to certain portions of this exhibit (indicated by asterisks), which have been separately filed with the Securities and Exchange Commission.

 *

 Certain confidential portions of this exhibit were omitted by means of marking such portions with brackets because the confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.

 SIGNATURES

 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.

 Date: March 29, 2024

 By:

 /s/ Justin Hall

 Justin Hall

 Chief Executive Officer, General Counsel and Director

 (principal executive officer)